Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.57 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 5/20 | 0.54 |
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.53 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.53 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461122 | 0.90 | PSMB1 (0.64) | CTSKPSMB1CTSLCTSSCTSB | |
| SCHEMBL4472685 | 0.88 | CTSK (0.56) | CTSKPSMB1CTSLCTSSCTSB | |
| SCHEMBL4491942 | 0.87 | CTSD (0.52) | CTSKCTSLCTSSCTSBREN | |
| SCHEMBL13925096 | 0.86 | CTSK (0.58) | CTSKPSMB1CTSLCTSSCTSB | |
| SCHEMBL4425542 | 0.85 | CTSK (0.62) | CTSKPSMB1CTSLCTSSCTSB | |
| SCHEMBL4485017 | 0.85 | CTSK (0.59) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL13914051 | 0.82 | CTSK (0.56) | CTSKPSMB1CTSLCTSSCTSB | |
| SCHEMBL4463849 | 0.82 | CTSK (0.52) | CTSKPSMB1CTSSCTSBREN | |
| SCHEMBL27564532 | 0.80 | CTSK (0.59) | CTSKPSMB1CTSLCTSSCTSB | |
| SCHEMBL6945614 | 0.79 | CTSK (0.79) | CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504382-B2 | Protease inhibitors for coronaviruses and SARS-CoV and the use thereof | CYTOVIA, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC. | 2008-12-04 | — | — | US | disclosed |
| EP-1628674-A2 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | Cytovia, Inc. (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004101742-A2 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | ACE, ACE2, TMPRSS2 | CTSK 72/4885PSMB1 686/4885CTSL 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.